Literature DB >> 19129408

Evaluation of an automated nucleic acid extractor for hepatitis C virus load quantification.

Elisa Martró1, Nerea García-Sierra, Victoria González, Verónica Saludes, Lurdes Matas, Vicenç Ausina.   

Abstract

The increasing use of molecular methods strongly motivates clinical laboratories to introduce automated nucleic acid extractors. We compared the easyMAG (bioMérieux) with a manual extraction method for hepatitis C virus (HCV) load quantification (RealTime HCV; Abbott). Both methods were comparable, and, therefore, the easyMAG is suitable to be implemented in our laboratory for the management of HCV-infected patients.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19129408      PMCID： PMC2650957          DOI： 10.1128/JCM.02181-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  9 in total

1.  Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD).

Authors:  Samuel S Lee; E Jenny Heathcote; K Rajender Reddy; Stefan Zeuzem; Michael W Fried; Teresa L Wright; Paul J Pockros; Dieter Häussinger; Coleman I Smith; Amy Lin; Stephen C Pappas
Journal:  J Hepatol       Date:  2002-10       Impact factor: 25.083

2.  Rapid and simple method for purification of nucleic acids.

Authors:  R Boom; C J Sol; M M Salimans; C L Jansen; P M Wertheim-van Dillen; J van der Noordaa
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

3.  Evaluation of NucliSens easyMAG for automated nucleic acid extraction from various clinical specimens.

Authors:  K Loens; K Bergs; D Ursi; H Goossens; M Ieven
Journal:  J Clin Microbiol       Date:  2006-12-13       Impact factor: 5.948

4.  Performance evaluation of the QIAGEN EZ1 DSP Virus Kit with Abbott RealTime HIV-1, HBV and HCV assays.

Authors:  George J Schneider; Kevin G Kuper; Klara Abravaya; Carolyn R Mullen; Marion Schmidt; Astrid Bunse-Grassmann; Markus Sprenger-Haussels
Journal:  J Clin Virol       Date:  2009-03-14       Impact factor: 3.168

5.  Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.

Authors:  Stefan Zeuzem; Maria Buti; Peter Ferenci; Jan Sperl; Yves Horsmans; Janusz Cianciara; Endre Ibranyi; Ola Weiland; Stephanie Noviello; Clifford Brass; Janice Albrecht
Journal:  J Hepatol       Date:  2005-11-07       Impact factor: 25.083

6.  Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

Authors:  José M Sánchez-Tapias; Moisés Diago; Pedro Escartín; Jaime Enríquez; Manuel Romero-Gómez; Rafael Bárcena; Javier Crespo; Raúl Andrade; Eva Martínez-Bauer; Ramón Pérez; Milagros Testillano; Ramón Planas; Ricard Solá; Manuel García-Bengoechea; Javier Garcia-Samaniego; Miguel Muñoz-Sánchez; Ricardo Moreno-Otero
Journal:  Gastroenterology       Date:  2006-08       Impact factor: 22.682

7.  Real-time PCR assays for hepatitis C virus (HCV) RNA quantitation are adequate for clinical management of patients with chronic HCV infection.

Authors:  Philippe Halfon; Marc Bourlière; Guillaume Pénaranda; Hacène Khiri; Denis Ouzan
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

8.  Evaluation of the analytical performance of the new Abbott RealTime RT-PCRs for the quantitative detection of HCV and HIV-1 RNA.

Authors:  M Schutten; E Fries; C Burghoorn-Maas; H G M Niesters
Journal:  J Clin Virol       Date:  2007-09-04       Impact factor: 3.168

9.  Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

Authors:  Mitchell L Shiffman; Fredy Suter; Bruce R Bacon; David Nelson; Hugh Harley; Ricard Solá; Stephen D Shafran; Karl Barange; Amy Lin; Ash Soman; Stefan Zeuzem
Journal:  N Engl J Med       Date:  2007-07-12       Impact factor: 91.245
  9 in total
  1 in total

Review 1.  Isothermal DNA amplification in vitro: the helicase-dependent amplification system.

Authors:  Yong-Joo Jeong; Kkothanahreum Park; Dong-Eun Kim
Journal:  Cell Mol Life Sci       Date:  2009-07-24       Impact factor: 9.261
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.